PNPLA3 rs738409 C>G 变异影响低骨骼肌量与 NAFLD 的关联:上海长风研究
该研究在 3969 名中国成人中采用定量超声测肝脂肪含量、以 NAFLD 纤维化评分、BARD 和 FIB-4 评估肝纤维化,并以体重校正四肢骨骼肌量(ASM%)衡量肌少症程度。结果显示低 ASM% 与 NAFLD 及肝纤维化相关,但该关联在 PNPLA3 GG 基因型携带者中分离。
要点
- 随 ASM% 四分位下降,男性 NAFLD 比例从 19.9% 升至 41.2%,女性从 26.3% 升至 42.3%(P < 0.001)。
- 低 ASM% 与 NAFLD 的关联在 PNPLA3 CC 和 CG 基因型中显著,在 GG 基因型携带者中不显著。
- 低 ASM% 与肝纤维化风险相关,但多重校正后不再显著。
核心结论
- 低 ASM% 与 NAFLD 和肝纤维化相关,但 PNPLA3 GG 基因型携带者中肌少症与 NAFLD 的关联分离。
- 基于 PNPLA3 基因型的分层可能有助于 NAFLD 的个体化治疗。
研究设计与样本
- 研究纳入 3969 名中国成人,采用定量超声测肝脂肪含量,以 NAFLD 纤维化评分、BARD 和 FIB-4 评分评估肝纤维化。
- 肌少症程度以体重校正四肢骨骼肌量(ASM% = 四肢骨骼肌量(kg)/体重(kg)×100%)衡量。
主要发现
- 随 ASM% 四分位下降,男性 NAFLD 比例从 19.9% 升至 41.2%,女性从 26.3% 升至 42.3%(P < 0.001)。
- 低 ASM% 与 NAFLD 的关联在 PNPLA3 CC 型(男性 OR 0.735 [0.610-0.885],女性 OR 0.812 [0.718-0.918],均 P = 0.001)和 CG 型(男性 OR 0.673 [0.573-0.790],女性 OR 0.798 [0.713-0.893],均 P < 0.001)显著,在 GG 型携带者中不显著。
- 校正年龄、吸烟、脂肪量、脂肪量与 ASM% 交互作用、肥胖、糖尿病及代谢综合征所有组分后,上述关联仍显著。
- 亚组分析发现,PNPLA3 GG 基因变异不增加低 ASM% 个体(无论肥胖状态)的 NAFLD 风险。
- 低 ASM% 增加肝纤维化风险(均 P < 0.05),但多重校正后不再显著。
临床怎么用
- 低 ASM% 与 NAFLD 和肝纤维化相关,提示肌少症评估可能对 NAFLD 风险分层有帮助。
- PNPLA3 GG 基因型携带者中肌少症与 NAFLD 关联分离,基于 PNPLA3 基因型的分层可能有助于 NAFLD 个体化治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Age-related skeletal muscle loss and patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphisms are both associated with increased liver steatosis and fibrosis in the absence of obesity. AIM: To investigate the influence of PNPLA3 polymorphism on the relationship between skeletal muscle loss and non-alcoholic fatty liver disease (NAFLD). METHODS: Liver fat content was measured using a quantitative ultrasound method, and liver fibrosis was assessed by NAFLD fibrosis, BARD and FIB-4 scores in 3969 Chinese adults. The degree of sarcopenia was measured by weight-adjusted appendicular skeletal muscle mass (ASM% = appendicular skeletal muscle mass(kg)/body weight(kg) 100%). RESULTS: The NAFLD proportion increased from 19.9% to 41.2% in men and 26.3% to 42.3% in women with decreasing ASM% quartiles (P < 0.001). Low ASM% was inversely associated with NAFLD in PNPLA3 CC (odds ratio [OR]: men, 0.735 [0.610-0.885] and women, 0.812 [0.718-0.918], both P = 0.001) and CG (OR: men, 0.673 [0.573-0.790] and women, 0.798 [0.713-0.893], both P < 0.001) but not GG genotype carriers. The association remained significant after adjustment for age, cigarette smoking, fat mass, interaction between fat mass and ASM%, obesity, diabetes and all components of metabolic syndrome. Subgroup analyses found that PNPLA3 GG gene variant did not increase the risk for NAFLD in individuals with low ASM% regardless of obesity status. Low ASM% also increased risk for liver fibrosis (all P < 0.05), which became insignificant after multiple adjustments. CONCLUSIONS: Low ASM% is associated with NAFLD and liver fibrosis. Dissociation of sarcopenia and NAFLD was found in PNPLA3 GG genotype carriers. A stratification based on PNPLA3 genotypes might facilitate personalised treatment for NAFLD.
引用
- Xia MF, Chen LY, Wu L, et al. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. Aliment Pharmacol Ther. 2019. PMID: 31250467. doi:10.1111/apt.15372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。